Evaluación de la eficacia y seguridad de la monoterapia con cloroquina para tratar malaria gestacional aguda no complicada debida P. vivax, Córdoba, Colombia, 2015-2017

Carmona-Fonseca J, Agudelo-García OM, Arango-Flórez E. Eficacia terapéutica y eventos adversos de tratamientos para malaria vivax y malaria falciparum en gestantes en las regiones de Urabá y Alto San Jorge, Colombia, 2008-2011. Rev Colomb Obs y Ginecol. 2013;64(1):27-37.

https://doi.org/10.18597/rcog.127

Carmona-Fonseca J, Maestre A. Incidencia de las malarias gestacional, congénita y placentaria en Urabá (Antioquia, Colombia).

https://doi.org/10.18597/rcog.351

World Health Organization (WHO). Methods for surveillance of antimalarial drug efficacy. Geneva: WHO; 2009.

World Health Organization (WHO). Compendium of who malaria guidance. Prevention, diagnosis, treatment, surveillance and elimination. Geneva: WHO; 2019.

Beutler E. Glucose-6-phosphate dehydrogenase deficiency. Diagnosis, clinical and genetic implications. Am J Clin Pathol. 1967;47(3):303-11. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/5335657

https://doi.org/10.1093/ajcp/47.3.303

Carmona-Fonseca J, Álvarez G, Ríos A, Vásquez MF. Deficiencia de glucosa 6-fostato deshidrogenasa en hombres sanos y en pacientes maláricos, Turbo (Antioquia, Colombia). Rev Bras Epidemiol. 2008;11(2):252-65. https://doi.org/10.1590/S1415-790X2008000200007

Carmona-Fonseca J, Alvarez G, Maestre A. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am J Trop Med Hyg. 2009;80(2):188-93. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19190211

https://doi.org/10.4269/ajtmh.2009.80.188

Duarte EC, Pang LW, Ribeiro LC, Fontes CJ. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg. 2001;65(5):471-6. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11716100

https://doi.org/10.4269/ajtmh.2001.65.471

Baird JK. Effectiveness of antimalarial drugs. N Engl J Med. 2005;352(15):1565-77. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15829537

https://doi.org/10.1056/NEJMra043207

Santos JB, Luz F, Deckers FA, Tauil PL. Subdoses of primaquine in overweight patients and malaria vivax relapses: Report of two cases in the Federal District, Brazil. Rev Soc Bras Med Trop. 2010;43(6):749-50. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21181040

https://doi.org/10.1590/S0037-86822010000600033

Orton L, Garner P. Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev. 2005/07/20. 2005;(3):CD004912. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16034957

World Health Organization (WHO). A general guide for the assessment of therapeutic efficacy of chloroquine for vivax malaria (working draft). Version 3. Geneva: WHO; 2001.

Ruebush TK, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am J Trop Med Hyg. 2003;69(5):548-52. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/14695094

https://doi.org/10.4269/ajtmh.2003.69.548

Phillips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis. 1996;23(5):1171-3. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/8922821

https://doi.org/10.1093/clinids/23.5.1171

Bergqvist Y, Domeij-Nyberg B. Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr. 1983;272(1):137-48. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/6841533

https://doi.org/10.1016/S0378-4347(00)86110-1

Whitby M. Drug resistant Plasmodium vivax malaria. J Antimicrob Chemother. 1997;40(6):749-52. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/9462425

https://doi.org/10.1093/jac/40.6.749

Garavelli PL, Corti E. Chloroquine resistance in Plasmodium vivax: The first case in Brazil. Trans R Soc Trop Med Hyg. 1992;86(2):128.

https://doi.org/10.1016/0035-9203(92)90535-K

Alecrim M das G, Alecrim W, Macêdo V. Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region. Rev Soc Bras Med Trop. 1999;32(1):67-8. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/9927829

https://doi.org/10.1590/S0037-86821999000100013

Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeño N, et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg. 2001;65(2):90-3. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11508397

https://doi.org/10.4269/ajtmh.2001.65.90

Ríos A, Álvarez G, Blair S. Diez años de eficacia terapéutica de la cloroquina en malaria no complicada por Plasmodium vivax, Turbo, Antioquia, años 2002 y 2011. Biomédica. 2013;33(3):429-38.

https://doi.org/10.7705/biomedica.v33i3.1631

Popovici J, Pierce-Friedrich L, Kim S, Bin S, Run V, Lek D, et al. Recrudescence, reinfection, or relapse? A more rigorous framework to assess chloroquine efficacy for plasmodium vivax malaria. J Infect Dis. 2019;219(2):315-22. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30102351

https://doi.org/10.1093/infdis/jiy484

Carmona-Fonseca J. Recurrencias de malaria por Plasmodium vivax según el uso de primaquina: análisis de estudios descriptivos longitudinales. Rev Bras Epidemiol. 2012;15(3):488-503.

https://doi.org/10.1590/S1415-790X2012000300005

Carmona-Fonseca J. Primaquine and relapses of Plasmodium vivax. Meta analysis of controlled clinical trials. Rev Bras Epidemiol. 2015;18(1):174-93. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25651020

https://doi.org/10.1590/1980-5497201500010014

Arias-Gómez J, Villasís-Keever MÁ, Miranda-Novales MG. El protocolo de investigación III: la población de estudio. Rev Alerg México. 2016;63(2):201-6.

https://doi.org/10.29262/ram.v63i2.181

Martínez-Bencardino C. Estadística y Muestreo (13 ed.). Bogotá: ECOE; 2012. p. 303-320.

Carmona-Fonseca J. Malaria vivax en niños: recurrencias con dosis total estándar de primaquina dada en 3 vs. 7 días. Iatreia. 2009;22(1):10-20.

Mesa-Echeverry E, Niebles-Bolivar M, Tobon-Castano A. Chloroquine-Primaquine therapeutic efficacy, safety, and plasma levels in patients with uncomplicated plasmodium vivax malaria in a colombian pacific region. Am J Trop Med Hyg. 2019;100(1):72-7.

https://doi.org/10.4269/ajtmh.18-0655

Carmona-Fonseca J, Maestre A. Prevention of Plasmodium vivax malaria recurrence: Efficacy of the standard total dose of primaquine administered over 3 days. Acta Trop. 2009;112(2):188-92. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19653988

https://doi.org/10.1016/j.actatropica.2009.07.024

Carmona-Fonseca J, Alvarez G, Blair S. Malaria por Plasmodium vivax: curación del ataque agudo con tres dosis diferentes de primaquina y dosis fija de cloroquina; Antioquia, Colombia, 2003-2004. Biomedica. 2006;26(3):353-65. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/17175999

https://doi.org/10.7705/biomedica.v26i3.354

Shokoples SE, Ndao M, Kowalewska-Grochowska K, Yanow SK. Multiplexed real-time PCR assay for discrimination of Plasmodium species with improved sensitivity for mixed infections. J Clin Microbiol. 2009;47(4):975-80.

https://doi.org/10.1128/JCM.01858-08

Lazcano-Ponce E, Salazar-Martinez E, Gutiérrez-Castrelló P, Angeles-Llerenas A, Hernández-Garduño A, Viramontes JL. Ensayos clínicos aleatorizados: variantes, métodos de aleatorización, análisis,consideraciones éticas y regulación. Salud Pública de México. 2004;46(6):559-84.

https://doi.org/10.1590/S0036-36342004000600012

Armijo-Olivo S, Warren S, Magee D. Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: A review. Phys Ther Rev. 2009;14(1):36-49.

https://doi.org/10.1179/174328809X405928

Zuluaga-Idárraga L, Blair S, Akinyi Okoth S, Udhayakumar V, Marcet PL, Escalante AA, et al. Prospective study of Plasmodium vivax malaria recurrence after radical treatment with a chloroquine-primaquine standard regimen in Turbo, Colombia. Antimicrob Agents Chemother. 2016;60(8):4610-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27185794

https://doi.org/10.1128/AAC.00186-16

Blair S, Tobón-Castaño A, Echeverri M, Alvarez Sánchez Bact G, Carmona-Fonseca J. Adecuada respuesta clínica y parasitológica de Plasmodium vivax a la cloroquina en Colombia (Turbo, Antioquia), 2001. 2002;6(1):21-6.

Castillo CM, Osorio LE, Palma GI. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a Malaria transmission free area in Colombia. Mem Inst Oswaldo Cruz. 2002;97(4):559-62.

https://doi.org/10.1590/S007402762002000400020

Pérez MA, Cortés LJ, Guerra AP, Knudson A, Usta C, Nicholls RS. Eficacia de la combinación amodiaquina más sulfadoxinapirimetamina y de la cloroquina para el tratamiento del paludismo en Córdoba, Colombia, 2006. Biomédica. 2008;28(1):148-59. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/699

https://doi.org/10.7705/biomedica.v28i1.699

Blair S, Tobón-Castaño A, Echeverri M, Alvarez Sánchez Bact G, Carmona-Fonseca J. Adecuada respuesta clínica y parasitológica de Plasmodium vivax a la cloroquina en Colombia (Turbo, Antioquia), 2001. 2002;6(1):21-6.

Alvarez G, Piñeros JG, Tobón A, Ríos A, Maestre A, Blair S, et al. Efficacy of three chloroquineprimaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am J Trop Med Hyg. 2006;75(4):605-9.

Barañao RI. Inmunología del embarazo. Invest Clin. 2011;52(2):175-94.

Racicot K, Kwon JY, Aldo P, Silasi M, Mor G. Understanding the complexity of the immune system during pregnancy. Am J Reprod Immunol. 2014;72(2):107-16. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24995526

https://doi.org/10.1111/aji.12289

Mor G, Cardenas I. The immune system in pregnancy: A unique complexity. Am J Reprod Immunol. 2010;63(6):425-33. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20367629

https://doi.org/10.1111/j.1600-0897.2010.00836.x

Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: A WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18(9):1025-34.

Nosten F, McGready R, d’Alessandro U, Bonell A, Verhoeff F, Menendez C. Antimalarial drugs in pregnancy: A review. Curr Drug Saf. 2006;1.

https://doi.org/10.2174/157488606775252584

Cooper RG. Chloroquine and pregnancy. Indian J Physiol Pharmacol. 2007;51(4):418-20.

WHO. World Health Organization. Guidelines for the treatment of malaria. 2 ed. Geneva: WHO; 2010.